Immunohistochemical study of the expression of drug-resistant proteins in large cell neuroendocrine carcinoma of the lung
The Japanese Journal of Thoracic and Cardiovascular Surgery · 2003
DOI: 10.1007/bf02719377 ↗At a glance
Vergleichsstudie in The Japanese Journal of Thoracic and Cardiovascular Surgery, 2003. Written by Daisuke Okada and 4 co-authors. Institution: Department of Pathology, Nippon Medical School, Tokyo, Japan. Cited 4 times so far (Crossref); 15 references.
Abstract (original language)
OBJECTIVES: In 1999, the World Health Organization categorized pulmonary large cell neuroendocrine carcinoma as a variant of large cell carcinoma. However, an optimal treatment for large cell neuroendocrine carcinoma has not been established yet. Recently, multimodality therapy combining both surgery and adjuvant chemotherapy has been reported as a useful treatment for large cell neuroendocrine carcinoma, but the effect of chemotherapy on it has not yet been fully investigated. Thus, we evaluated immunohistochemical data of the expression of drug-resistant proteins in large cell neuroendocrine carcinoma. METHODS: We identified 10 large cell neuroendocrine carcinomas (1.2%) out of 850 primary lung cancers that had been surgically resected. We examined the immunohistochemical staining of three drug-resistant proteins, namely, P-glycoprotein, metallothionein and glutathione S-transferase-pi to compare large cell neuroendocrine carcinoma with other histological types of lung cancer. RESULTS: The mean tumor cell positivity rates for P-glycoprotein, metallothionein and glutathione S-transferase-pi in large cell neuroendocrine carcinoma were 0%, 2.4 +/- 3.6% and 35.0 +/- 37.5%, respectively. The positivity rates for P-glycoprotein and glutathione S-transferase-pi were significantly lower than those in adenocarcinoma (P = 0.0003, P = 0.0009). The positivity rate for glutathione S-transferase-pi was also lower than that in squamous cell carcinoma (P = 0.0387). These drug-resistant proteins showed similar expression pattern in both large cell neuroendocrine carcinoma and small cell carcinoma except glutathione S-transferase-pi. CONCLUSION: Immunohistochemical expression of drug-resistant proteins in large cell neuroendocrine carcinoma was lower than that in adenocarcinoma and squamous cell carcinoma, and differences exist in drug-resistance between large cell neuroendocrine carcinoma and small cell carcinoma.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Department of Pathology, Nippon Medical School, Tokyo, Japan.
Cite
APA
Okada, D., Kawamoto, M., Koizumi, K., Tanaka, S., & Fukuda, Y. (2003). Immunohistochemical study of the expression of drug-resistant proteins in large cell neuroendocrine carcinoma of the lung. The Japanese Journal of Thoracic and Cardiovascular Surgery. https://doi.org/10.1007/bf02719377
Vancouver
Okada D, Kawamoto M, Koizumi K, Tanaka S, Fukuda Y. Immunohistochemical study of the expression of drug-resistant proteins in large cell neuroendocrine carcinoma of the lung. The Japanese Journal of Thoracic and Cardiovascular Surgery. 2003. doi:10.1007/bf02719377
BibTeX
@article{Okada2003,
author = {Okada, Daisuke and Kawamoto, Masashi and Koizumi, Kiyoshi and Tanaka, Shigeo and Fukuda, Yuh},
title = {Immunohistochemical study of the expression of drug-resistant proteins in large cell neuroendocrine carcinoma of the lung},
journal = {The Japanese Journal of Thoracic and Cardiovascular Surgery},
year = {2003},
doi = {10.1007/bf02719377}
}
EUVIMED